These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 35955847)

  • 1. Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders.
    De Plano LM; Calabrese G; Conoci S; Guglielmino SPP; Oddo S; Caccamo A
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicle and CRISPR gene therapy: Current applications in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease.
    Akyuz E; Aslan FS; Gokce E; Ilmaz O; Topcu F; Kakac S
    Eur J Neurosci; 2024 Oct; 60(8):6057-6090. PubMed ID: 39297377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
    Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CRISPR/Cas9 to model brain diseases.
    Yan S; Tu Z; Li S; Li XJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():488-492. PubMed ID: 28392484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases.
    Karimian A; Gorjizadeh N; Alemi F; Asemi Z; Azizian K; Soleimanpour J; Malakouti F; Targhazeh N; Majidinia M; Yousefi B
    Life Sci; 2020 Oct; 259():118165. PubMed ID: 32735884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders.
    Guan L; Han Y; Yang C; Lu S; Du J; Li H; Lin J
    Mol Neurobiol; 2022 Feb; 59(2):968-982. PubMed ID: 34813019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How CRISPR gene editing could help treat Alzheimer's.
    Thompson T
    Nature; 2024 Jan; 625(7993):13-14. PubMed ID: 38082131
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.
    Kuruvilla J; Sasmita AO; Ling APK
    Neurol Sci; 2018 Nov; 39(11):1827-1835. PubMed ID: 30076486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 genome editing for neurodegenerative diseases.
    Nouri Nojadeh J; Bildiren Eryilmaz NS; Ergüder BI
    EXCLI J; 2023; 22():567-582. PubMed ID: 37636024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics.
    Bhardwaj S; Kesari KK; Rachamalla M; Mani S; Ashraf GM; Jha SK; Kumar P; Ambasta RK; Dureja H; Devkota HP; Gupta G; Chellappan DK; Singh SK; Dua K; Ruokolainen J; Kamal MA; Ojha S; Jha NK
    J Adv Res; 2022 Sep; 40():207-221. PubMed ID: 36100328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models.
    Barazesh M; Mohammadi S; Bahrami Y; Mokarram P; Morowvat MH; Saidijam M; Karimipoor M; Kavousipour S; Vosoughi AR; Khanaki K
    Curr Gene Ther; 2021; 21(2):130-148. PubMed ID: 33319680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 in Alzheimer's disease: Therapeutic trends, modalities, and challenges.
    Chacko L; Chaudhary A; Singh B; Dewanjee S; Kandimalla R
    Drug Discov Today; 2023 Aug; 28(8):103652. PubMed ID: 37290639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease.
    Park H; Oh J; Shim G; Cho B; Chang Y; Kim S; Baek S; Kim H; Shin J; Choi H; Yoo J; Kim J; Jun W; Lee M; Lengner CJ; Oh YK; Kim J
    Nat Neurosci; 2019 Apr; 22(4):524-528. PubMed ID: 30858603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment.
    Tripathi S; Sharma Y; Rane R; Kumar D
    CNS Neurol Disord Drug Targets; 2024; 23(12):1405-1424. PubMed ID: 38716549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer's, Parkinson's, and Huntington's Diseases and Amyotrophic Lateral Sclerosis.
    Ciurea AV; Mohan AG; Covache-Busuioc RA; Costin HP; Glavan LA; Corlatescu AD; Saceleanu VM
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Broad Application of CRISPR Cas9 in Infectious, Inflammatory and Neurodegenerative Diseases.
    Pahan K
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):534-536. PubMed ID: 31782056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform.
    Garcia-Leon JA; Vitorica J; Gutierrez A
    Future Med Chem; 2019 Jun; 11(11):1305-1322. PubMed ID: 31161803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.